The nomenclature is based on the phospho‐epitopes recognized by antibodies raised against tau from AD brains (AT8, AT100, or PHF‐1) when tau is phosphorylated at specific sites at either flanking domain of the repeats (Bibow et al., 2011). Here, MAPT is linked to Alzheimer disease.